Loading
Olaparib shrank some metastatic breast cancers with tumour-only BRCA mutations. This does not establish benefit in preventing recurrence after surgery.
Phase 2 expansion with 24 germline PALB2 and 30 somatic BRCA1/2 participants. The overall population comprised 42 ER-positive/HER2-negative, seven TNBC and five HER2-positive cancers. Participants received single-agent olaparib until progression. Somatic-BRCA activity was clinically meaningful but missed the prespecified response target.
Metastatic single-arm evidence does not supply a somatic-only adjuvant indication or a personal response probability.
Shares PARP, Olaparib, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Olaparib, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Olaparib, Breast cancer (all types).
Shares PARP, Olaparib, Breast cancer (all types).
Shares PARP, Olaparib, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Olaparib, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/